Converting HR+ Breast Cancer Into an Individualized Vaccine

Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.

Trial Details

NCT ID
NCT03804944
Phase
PHASE2
Sponsor
Weill Medical College of Cornell University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Focal Radiation therapy
  • Pembrolizumab (200mg IV for 30 minutes
  • CDX-301
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Post-menopausal female ≥ 18 years of age (Post-menopausal status defined as either 1) at least 2 years without menstrual period or 2) or patients o…
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Biopsy proven diagnosis of ER+ PR+ or PR- HER2- breast cancer.
  • Clinical stage I(\>1.5cm, if N0) - III breast cancer, as per AJCC staging 8th edition.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →